Amylyx Pharmaceuticals, Inc. AMLX ("Amylyx" or the "Company") announced today that a new post hoc analysis measuring substantial individual response to AMX0035 (sodium phenylbutyrate [PB] and taurursodiol [TURSO; also known as ursodoxicoltaurine]) will be presented at the European Network to Cure ALS (ENCALS) 2022 Meeting on June 2, 2022 in Edinburgh, Scotland.